Literature DB >> 15605208

Practical approach to the therapy of systemic sclerosis.

L Czirják1.   

Abstract

Systemic sclerosis (SSc) is characterised by vascular abnormalities, fibrosis, inflammatory changes, and atrophy affecting the skin and several internal organs. The course of the disease is highly variable from patient to patient, and the different organ manifestations may show a different stage of activity and damage. More extensive skin involvement coincides with more severe internal organ manifestation(s) resulting in an unfavourable outcome of disease. Subset classification and organ system involvements should be carefully determined before introducing the therapy. Prognostic evaluation, including the staging of disease severity, damage, activity and the definition of longitudinal disease behaviour of the organ manifestations (by serial investigations) is also crucial. Theoretically the treatment should focus on both the early reduction of inflammatory phenomena and influence of vascular symptoms to prevent the development of tissue fibrosis and atrophy. Major internal organ manifestations including gastro-oesophageal reflux, scleroderma renal involvement, different cardio-respiratory disorders should also be carefully looked for, and early signs of internal organ involvements should be recognized and treated. There is no disease modifying drug therapy of proven efficacy in SSc but an individualized, well designed therapy may be remarkably efficient in terms of improving the prognosis and quality of life of patients. Education of patients is also compelling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605208     DOI: 10.1007/s00393-004-0672-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.

Authors:  A Della Rossa; G Valentini; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; R Becvar; P Bruhlman; F Cozzi; L Czirják; A A Drosos; B Dziankowska; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; R Scorza; E Tirri; F H van den Hoogen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

3.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

Authors:  F H van den Hoogen; A M Boerbooms; A J Swaak; J J Rasker; H J van Lier; L B van de Putte
Journal:  Br J Rheumatol       Date:  1996-04

4.  Watermelon-stomach as a cause of chronic iron deficiency anemia in a patient with systemic sclerosis.

Authors:  G Fábián; E Tóvári; F Baranyay; L Czirják
Journal:  J Eur Acad Dermatol Venereol       Date:  1999-03       Impact factor: 6.166

5.  Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.

Authors:  H Zachariae; L Halkier-Sørensen; P Bjerring; L Heickendorff
Journal:  Acta Derm Venereol       Date:  1996-05       Impact factor: 4.437

6.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

7.  Simultaneous presence of neutrophil alveolitis and Ki-67 positivity of alveolar macrophages in dermato-/polymyositis and systemic sclerosis.

Authors:  Gábor Kumánovics; Tamás Magyarlaki; András Komócsi; György Szekeres; László Czirják
Journal:  Rheumatol Int       Date:  2002-09-11       Impact factor: 2.631

8.  Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.

Authors:  L Bettoni; A Geri; P Airò; E Danieli; I Cavazzana; C Antonioli; L Chiesa; F Franceschini; A Grottolo; A Zambruni; E Radaeli; R Cattaneo
Journal:  Clin Rheumatol       Date:  2002-06       Impact factor: 2.980

9.  Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis.

Authors:  J Gaál; I Hegedüs; K Dévényi; L Czirják
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

10.  Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.

Authors:  D E Furst; P J Clements; S Hillis; P A Lachenbruch; B L Miller; M G Sterz; H E Paulus
Journal:  Arthritis Rheum       Date:  1989-05
View more
  1 in total

1.  [Systemic sclerosis].

Authors:  B A Michel
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.